Clinical Trials
20 trialsNCT06254326 2026-05-27
ADAGiO
University of Florida
Phase 1 Recruiting
NCT03911388 2026-05-15
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT03975829 2026-05-11
Pediatric Long-Term Follow-up and Rollover Study
Novartis
Phase 4 Recruiting
NCT05190172 2026-05-01
PRO-GLIO
Oslo University Hospital
Phase NA Recruiting
NCT07462507 2026-04-21
Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
Washington University School of Medicine
Phase 2 Recruiting
NCT05698524 2026-04-17
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
University of Nebraska
Phase 1 Recruiting
NCT05303519 2026-03-05
SIGMA
Nuvation Bio Inc.
Phase 3 Recruiting
NCT05345002 2026-02-20
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT04923126 2026-02-04
SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT05331521 2026-02-03
ImproveCodel
University Hospital Heidelberg
Phase 3 Recruiting
NCT04702581 2026-01-29
POLO
Hospices Civils de Lyon
Phase 3 Recruiting
NCT04623931 2026-01-14
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04541082 2025-12-18
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Jazz Pharmaceuticals
Phase 1 Recruiting
NCT05956821 2025-12-08
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
University of Miami
Phase 1/2 Recruiting
NCT06930846 2025-11-21
HOBSCOTCH-CA
Dartmouth-Hitchcock Medical Center
Phase NA Recruiting
NCT06989086 2025-09-09
FearLess in NeuroOncology
Virginia Commonwealth University
Phase NA Recruiting
NCT04135807 2025-07-23
Implantable Microdevice In Primary Brain Tumors
Brigham and Women's Hospital
Phase EARLY_PHASE1 Recruiting
NCT06161974 2025-02-21
Study of Olutasidenib and Temozolomide in HGG
Rigel Pharmaceuticals
Phase 2 Recruiting
NCT05512351 2022-09-27
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma
Henan Provincial People's Hospital
Phase 2 Recruiting
NCT01649830 2020-05-28
Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma
Sun Yat-sen University
Phase 3 Recruiting